Last updated: 11/07/2018 00:48:45
A phase I study to determine the maximum tolerated doses of paclitaxel, cisplatin and topotecan (PTC) administered intravenously every 21 days as first line therapy in patients with advanced (stage III and IV) ovarian carcinoma.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A phase I study to determine the maximum tolerated doses of paclitaxel, cisplatin and topotecan (PTC) administered intravenously every 21 days as first line therapy in patients with advanced (stage III and IV) ovarian carcinoma.
Trial description: A phase I study to determine the maximum tolerated doses of paclitaxel, cisplatin and topotecan (PTC) administered intravenously every 21 days as first line therapy in patients with advanced (stage III and IV) ovarian carcinoma.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, et al. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J Clin Oncol 1999;17(3):74755.
ten Bokkel Huinink WW, Richel DJ, Herben VM, et al. Feasibility study of the combination of cisplatin, paclitaxel and topotecan in ovarian cancer patients Proc ASCO 1998; 17: 351a (Abstract 1353)
Medical condition
Neoplasms, Ovarian
Product
topotecan
Collaborators
Not applicable
Study date(s)
May 1996 to February 1999
Type
Not applicable
Phase
1
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1999-05-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website